Intellia Therapeutics (NTLA) Receivables - Other (2015 - 2023)

Intellia Therapeutics (NTLA) has 9 years of Receivables - Other data on file, last reported at $1.0 million in Q4 2023.

• Receivables - Other for Q4 2023 came in at $1.0 million, down 37.5% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.0 million (down 37.5% YoY), and the FY2023 annual result was $1.0 million, up 900.0% from the prior year.
• Receivables - Other held at $1.0 million in Q4 2023 per NTLA's latest filing, from $1.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $8.4 million in Q1 2020 and troughed at $300000.0 in Q1 2023.
• A 5-year average of $2.1 million and a median of $1.4 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2020 and 2021: Receivables - Other surged 740.0% in 2020, then tumbled 88.1% in 2021.
• A 5-year view of Receivables - Other shows it stood at $3.6 million in 2019, then plunged by 41.67% to $2.1 million in 2020, then changed by 0.0% to $2.1 million in 2021, then slipped by 23.81% to $1.6 million in 2022, then tumbled by 37.5% to $1.0 million in 2023.
• Business Quant data shows NTLA's Receivables - Other at $1.0 million in Q4 2023, $1.0 million in Q3 2023, and $1.4 million in Q2 2023.